You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
INDICATIONS AS AT 24 FEBRUARY 2004: KEFLEX is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by S. pneumoniae and group A beta-haemolytic streptococci (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. KEFLEX is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of KEFLEX in the subsequent prevention of rheumatic fever are not available at present.) Bacterial sinusitis caused by streptococci, S. pneumoniae and S. aureus (methicillin-sensitive only) Otitis media due to S. pneumoniae, staphylococci; Skin and soft tissue infections caused by staphlococci anr/or streptococci; Genitourinary tract infections, including acute prostatic caused by E. coli, P. mirabilis, and Klebsiella sp. The effectiveness of KEFLEX in the treatment of bacterial infections of the brain and spinal column has not been established and KEFLEX is not indicated in these conditions. NOTE: Appropriate culture and susceptibility test should be initiated prior to and during therapy to determine susceptibility of the causative organism to KEFLEX. Renal function studies should be performed when indicated.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
This medicine is generally considered safe during pregnancy if taken as directed. During pregnancy, you should discuss your medicine use with your doctor or pharmacist.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
INDICATIONS AS AT 24 FEBRUARY 2004: KEFLEX is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by S. pneumoniae and group A beta-haemolytic streptococci (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. KEFLEX is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of KEFLEX in the subsequent prevention of rheumatic fever are not available at present.) Bacterial sinusitis caused by streptococci, S. pneumoniae and S. aureus (methicillin-sensitive only) Otitis media due to S. pneumoniae, staphylococci; Skin and soft tissue infections caused by staphlococci anr/or streptococci; Genitourinary tract infections, including acute prostatic caused by E. coli, P. mirabilis, and Klebsiella sp. The effectiveness of KEFLEX in the treatment of bacterial infections of the brain and spinal column has not been established and KEFLEX is not indicated in these conditions. NOTE: Appropriate culture and susceptibility test should be initiated prior to and during therapy to determine susceptibility of the causative organism to KEFLEX. Renal function studies should be performed when indicated.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
This medicine is generally considered safe during pregnancy if taken as directed. During pregnancy, you should discuss your medicine use with your doctor or pharmacist.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
INDICATIONS AS AT 24 FEBRUARY 2004: KEFLEX is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by S. pneumoniae and group A beta-haemolytic streptococci (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. KEFLEX is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of KEFLEX in the subsequent prevention of rheumatic fever are not available at present.) Bacterial sinusitis caused by streptococci, S. pneumoniae and S. aureus (methicillin-sensitive only) Otitis media due to S. pneumoniae, staphylococci; Skin and soft tissue infections caused by staphlococci anr/or streptococci; Genitourinary tract infections, including acute prostatic caused by E. coli, P. mirabilis, and Klebsiella sp. The effectiveness of KEFLEX in the treatment of bacterial infections of the brain and spinal column has not been established and KEFLEX is not indicated in these conditions. NOTE: Appropriate culture and susceptibility test should be initiated prior to and during therapy to determine susceptibility of the causative organism to KEFLEX. Renal function studies should be performed when indicated.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
This medicine is generally considered safe during pregnancy if taken as directed. During pregnancy, you should discuss your medicine use with your doctor or pharmacist.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
INDICATIONS AS AT 24 FEBRUARY 2004: KEFLEX is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by S. pneumoniae and group A beta-haemolytic streptococci (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. KEFLEX is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of KEFLEX in the subsequent prevention of rheumatic fever are not available at present.) Bacterial sinusitis caused by streptococci, S. pneumoniae and S. aureus (methicillin-sensitive only) Otitis media due to S. pneumoniae, staphylococci; Skin and soft tissue infections caused by staphlococci anr/or streptococci; Genitourinary tract infections, including acute prostatic caused by E. coli, P. mirabilis, and Klebsiella sp. The effectiveness of KEFLEX in the treatment of bacterial infections of the brain and spinal column has not been established and KEFLEX is not indicated in these conditions. NOTE: Appropriate culture and susceptibility test should be initiated prior to and during therapy to determine susceptibility of the causative organism to KEFLEX. Renal function studies should be performed when indicated.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
This medicine is generally considered safe during pregnancy if taken as directed. During pregnancy, you should discuss your medicine use with your doctor or pharmacist.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
INDICATIONS AS AT 24 FEBRUARY 2004: KEFLEX is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by S. pneumoniae and group A beta-haemolytic streptococci (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. KEFLEX is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of KEFLEX in the subsequent prevention of rheumatic fever are not available at present.) Bacterial sinusitis caused by streptococci, S. pneumoniae and S. aureus (methicillin-sensitive only) Otitis media due to S. pneumoniae, staphylococci; Skin and soft tissue infections caused by staphlococci anr/or streptococci; Genitourinary tract infections, including acute prostatic caused by E. coli, P. mirabilis, and Klebsiella sp. The effectiveness of KEFLEX in the treatment of bacterial infections of the brain and spinal column has not been established and KEFLEX is not indicated in these conditions. NOTE: Appropriate culture and susceptibility test should be initiated prior to and during therapy to determine susceptibility of the causative organism to KEFLEX. Renal function studies should be performed when indicated.
This medicine is generally considered safe during pregnancy if taken as directed. During pregnancy, you should discuss your medicine use with your doctor or pharmacist.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
INDICATIONS AS AT 24 FEBRUARY 2004: KEFLEX is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by S. pneumoniae and group A beta-haemolytic streptococci (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. KEFLEX is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of KEFLEX in the subsequent prevention of rheumatic fever are not available at present.) Bacterial sinusitis caused by streptococci, S. pneumoniae and S. aureus (methicillin-sensitive only) Otitis media due to S. pneumoniae, staphylococci; Skin and soft tissue infections caused by staphlococci anr/or streptococci; Genitourinary tract infections, including acute prostatic caused by E. coli, P. mirabilis, and Klebsiella sp. The effectiveness of KEFLEX in the treatment of bacterial infections of the brain and spinal column has not been established and KEFLEX is not indicated in these conditions. NOTE: Appropriate culture and susceptibility test should be initiated prior to and during therapy to determine susceptibility of the causative organism to KEFLEX. Renal function studies should be performed when indicated.
This medicine is generally considered safe during pregnancy if taken as directed. During pregnancy, you should discuss your medicine use with your doctor or pharmacist.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
